Fondazione Istituto di Ricerca Pediatrica-Città della Speranza, 35127 Padova, Italy.
Infectious Disease Unit, Padova University Hospital, 35128 Padova, Italy.
Viruses. 2022 Mar 9;14(3):565. doi: 10.3390/v14030565.
Vaccination with an mRNA COVID-19 vaccine determines not only a consistent reduction in the risk of SARS-CoV-2 infection but also contributes to disease attenuation in infected people. Of note, hyperinflammation and damage-associated molecular patterns (DAMPs) have been clearly associated with severe illness and poor prognosis in COVID-19 patients. In this report, we revealed a significant reduction in the levels of IL-1ß and DAMPs molecules, as S100A8 and High Mobility Group Protein B1 (HMGB1), in vaccinated patients as compared to non-vaccinated ones. COVID-19 vaccination indeed prevents severe clinical manifestations in patients and limits the release of systemic danger signals in SARS-CoV-2 infected people.
接种 mRNA COVID-19 疫苗不仅能显著降低 SARS-CoV-2 感染风险,还能减轻感染者的疾病严重程度。值得注意的是,过度炎症反应和损伤相关分子模式(DAMPs)与 COVID-19 患者的重症和不良预后密切相关。在本报告中,我们发现与未接种疫苗者相比,接种疫苗者的白细胞介素 1β(IL-1ß)和 DAMPs 分子(S100A8 和高迁移率族蛋白 B1(HMGB1))水平显著降低。COVID-19 疫苗接种确实可以预防患者出现严重的临床症状,并限制 SARS-CoV-2 感染者全身性危险信号的释放。